Skip to main content
Erschienen in: Drugs & Aging 11/2019

08.10.2019 | Current Opinion

Is Testosterone Replacement Therapy in Older Men Effective and Safe?

verfasst von: Andriy Yabluchanskiy, Panayiotis D. Tsitouras

Erschienen in: Drugs & Aging | Ausgabe 11/2019

Einloggen, um Zugang zu erhalten

Abstract

The number of older adults over 65 years of age is expected to increase to almost 100 million in the US by 2050, more than double the current figure of 46 million. Advanced age is associated with increased frailty among older Americans and often leads to increased disability, hospitalization, institutionalization, and, eventually, mortality. In search of means to improve age-related risks for adverse health outcomes, the question of restoring diminishing sex hormones has gathered much interest and has led to the practice of sex hormone replacement therapies in older men. Recent data suggest that androgen prescription rates in the US for men older than 60 years of age quadrupled from the years 2001 to 2011. While prescription sales of testosterone have increased from $150 million in 2000 to $1.8 billion in 2011, a significant portion of men prescribed testosterone replacement therapy did not meet the laboratory criteria for hypogonadism. While some clinical trials reported an association between testosterone insufficiency in older men and increased risk of death, the exact effects and consequences of testosterone replacement therapy, specifically in older men, remain unclear. This review is aimed at discussing the possible benefits and complications of testosterone replacement therapy in older men over 60 years of age.
Literatur
1.
Zurück zum Zitat Bergman H, et al. Understanding and meeting the needs of the older population: a global challenge. Can Geriatr J. 2013;16(2):61–5.PubMedPubMedCentral Bergman H, et al. Understanding and meeting the needs of the older population: a global challenge. Can Geriatr J. 2013;16(2):61–5.PubMedPubMedCentral
2.
Zurück zum Zitat Sierra F, Kohanski R. Geroscience and the trans-NIH Geroscience Interest Group, GSIG. Geroscience. 2017;39(1):1–5.PubMedPubMedCentral Sierra F, Kohanski R. Geroscience and the trans-NIH Geroscience Interest Group, GSIG. Geroscience. 2017;39(1):1–5.PubMedPubMedCentral
3.
Zurück zum Zitat Yabluchanskiy A, et al. Advances and challenges in geroscience research: an update. Physiol Int. 2018;105(4):298–308.PubMed Yabluchanskiy A, et al. Advances and challenges in geroscience research: an update. Physiol Int. 2018;105(4):298–308.PubMed
4.
Zurück zum Zitat Colby SL, Ortman JM. Projections of the Size and Composition of the US Population: 2014 to 2060. US Department of Commerce, Economics and Statistics Administration, US Census Bureau; 2015. pp. 1–13. Colby SL, Ortman JM. Projections of the Size and Composition of the US Population: 2014 to 2060. US Department of Commerce, Economics and Statistics Administration, US Census Bureau; 2015. pp. 1–13.
5.
Zurück zum Zitat Aristophanes L. 1994: Dover edition. Dover ed. New York: Dover; 1994. Aristophanes L. 1994: Dover edition. Dover ed. New York: Dover; 1994.
6.
Zurück zum Zitat Clegg A, et al. Frailty in elderly people. Lancet. 2013;381(9868):752–62. Clegg A, et al. Frailty in elderly people. Lancet. 2013;381(9868):752–62.
7.
Zurück zum Zitat Perry HM 3rd, et al. Testosterone and leptin in older African-American men: relationship to age, strength, function, and season. Metabolism. 2000;49(8):1085–91.PubMed Perry HM 3rd, et al. Testosterone and leptin in older African-American men: relationship to age, strength, function, and season. Metabolism. 2000;49(8):1085–91.PubMed
8.
Zurück zum Zitat Morley JE, Perry HM 3rd. Androgen deficiency in aging men: role of testosterone replacement therapy. J Lab Clin Med. 2000;135(5):370–8.PubMed Morley JE, Perry HM 3rd. Androgen deficiency in aging men: role of testosterone replacement therapy. J Lab Clin Med. 2000;135(5):370–8.PubMed
9.
10.
Zurück zum Zitat Pardridge WM, Landaw EM. Testosterone transport in brain: primary role of plasma protein-bound hormone. Am J Physiol. 1985;249(5 Pt 1):E534–42.PubMed Pardridge WM, Landaw EM. Testosterone transport in brain: primary role of plasma protein-bound hormone. Am J Physiol. 1985;249(5 Pt 1):E534–42.PubMed
11.
Zurück zum Zitat Harman SM, et al. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab. 2001;86(2):724–31.PubMed Harman SM, et al. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab. 2001;86(2):724–31.PubMed
12.
Zurück zum Zitat Winters SJ, Sherins RJ, Troen P. The gonadotropin-suppressive activity of androgen is increased in elderly men. Metabolism. 1984;33(11):1052–9.PubMed Winters SJ, Sherins RJ, Troen P. The gonadotropin-suppressive activity of androgen is increased in elderly men. Metabolism. 1984;33(11):1052–9.PubMed
13.
Zurück zum Zitat Neaves WB, et al. Leydig cell numbers, daily sperm production, and serum gonadotropin levels in aging men. J Clin Endocrinol Metab. 1984;59(4):756–63.PubMed Neaves WB, et al. Leydig cell numbers, daily sperm production, and serum gonadotropin levels in aging men. J Clin Endocrinol Metab. 1984;59(4):756–63.PubMed
14.
Zurück zum Zitat Harman SM, Tsitouras PD. Reproductive hormones in aging men. I. Measurement of sex steroids, basal luteinizing hormone, and Leydig cell response to human chorionic gonadotropin. J Clin Endocrinol Metab. 1980;51(1):35–40.PubMed Harman SM, Tsitouras PD. Reproductive hormones in aging men. I. Measurement of sex steroids, basal luteinizing hormone, and Leydig cell response to human chorionic gonadotropin. J Clin Endocrinol Metab. 1980;51(1):35–40.PubMed
15.
Zurück zum Zitat Baillargeon J, et al. Trends in androgen prescribing in the United States, 2001 to 2011. JAMA Intern Med. 2013;173(15):1465–6.PubMedPubMedCentral Baillargeon J, et al. Trends in androgen prescribing in the United States, 2001 to 2011. JAMA Intern Med. 2013;173(15):1465–6.PubMedPubMedCentral
16.
Zurück zum Zitat Bandari J, et al. Marketing and Testosterone Treatment in the USA: a systematic review. Eur Urol Focus. 2017;3(4–5):395–402.PubMed Bandari J, et al. Marketing and Testosterone Treatment in the USA: a systematic review. Eur Urol Focus. 2017;3(4–5):395–402.PubMed
17.
Zurück zum Zitat Surampudi PN, Wang C, Swerdloff R. Hypogonadism in the aging male diagnosis, potential benefits, and risks of testosterone replacement therapy. Int J Endocrinol. 2012;2012:625434.PubMedPubMedCentral Surampudi PN, Wang C, Swerdloff R. Hypogonadism in the aging male diagnosis, potential benefits, and risks of testosterone replacement therapy. Int J Endocrinol. 2012;2012:625434.PubMedPubMedCentral
18.
Zurück zum Zitat Wu FC, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med. 2010;363(2):123–35.PubMed Wu FC, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med. 2010;363(2):123–35.PubMed
19.
Zurück zum Zitat Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab. 2008;93(1):68–75.PubMed Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab. 2008;93(1):68–75.PubMed
20.
Zurück zum Zitat Bhasin S, Woodhouse L, Storer TW. Proof of the effect of testosterone on skeletal muscle. J Endocrinol. 2001;170(1):27–38.PubMed Bhasin S, Woodhouse L, Storer TW. Proof of the effect of testosterone on skeletal muscle. J Endocrinol. 2001;170(1):27–38.PubMed
21.
Zurück zum Zitat Srinivas-Shankar U, et al. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2010;95(2):639–50.PubMed Srinivas-Shankar U, et al. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2010;95(2):639–50.PubMed
22.
Zurück zum Zitat Snyder PJ, et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab. 1999;84(6):1966–72.PubMed Snyder PJ, et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab. 1999;84(6):1966–72.PubMed
23.
Zurück zum Zitat Page ST, et al. Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab. 2005;90(3):1502–10.PubMed Page ST, et al. Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab. 2005;90(3):1502–10.PubMed
24.
Zurück zum Zitat Storer TW, et al. Effects of testosterone supplementation for 3 years on muscle performance and physical function in older men. J Clin Endocrinol Metab. 2017;102(2):583–93.PubMed Storer TW, et al. Effects of testosterone supplementation for 3 years on muscle performance and physical function in older men. J Clin Endocrinol Metab. 2017;102(2):583–93.PubMed
25.
Zurück zum Zitat Travison TG, et al. Clinical meaningfulness of the changes in muscle performance and physical function associated with testosterone administration in older men with mobility limitation. J Gerontol A Biol Sci Med Sci. 2011;66(10):1090–9.PubMed Travison TG, et al. Clinical meaningfulness of the changes in muscle performance and physical function associated with testosterone administration in older men with mobility limitation. J Gerontol A Biol Sci Med Sci. 2011;66(10):1090–9.PubMed
26.
Zurück zum Zitat Bhasin S, et al. Effect of testosterone replacement on measures of mobility in older men with mobility limitation and low testosterone concentrations: secondary analyses of the Testosterone Trials. Lancet Diabetes Endocrinol. 2018;6(11):879–90.PubMed Bhasin S, et al. Effect of testosterone replacement on measures of mobility in older men with mobility limitation and low testosterone concentrations: secondary analyses of the Testosterone Trials. Lancet Diabetes Endocrinol. 2018;6(11):879–90.PubMed
27.
Zurück zum Zitat Amory JK, et al. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab. 2004;89(2):503–10.PubMed Amory JK, et al. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab. 2004;89(2):503–10.PubMed
28.
Zurück zum Zitat Snyder PJ, et al. Effect of testosterone treatment on volumetric bone density and strength in older men with low testosterone: a controlled clinical trial. JAMA Intern Med. 2017;177(4):471–9.PubMedPubMedCentral Snyder PJ, et al. Effect of testosterone treatment on volumetric bone density and strength in older men with low testosterone: a controlled clinical trial. JAMA Intern Med. 2017;177(4):471–9.PubMedPubMedCentral
29.
Zurück zum Zitat Brock G, et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo controlled study. J Urol. 2016;195(3):699–705.PubMed Brock G, et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo controlled study. J Urol. 2016;195(3):699–705.PubMed
30.
Zurück zum Zitat Cunningham GR, et al. Testosterone treatment and sexual function in older men with low testosterone levels. J Clin Endocrinol Metab. 2016;101(8):3096–104.PubMedPubMedCentral Cunningham GR, et al. Testosterone treatment and sexual function in older men with low testosterone levels. J Clin Endocrinol Metab. 2016;101(8):3096–104.PubMedPubMedCentral
31.
32.
Zurück zum Zitat Basaria S, et al. Effects of testosterone administration for 3 years on subclinical atherosclerosis progression in older men with low or low-normal testosterone levels: a randomized clinical trial. JAMA. 2015;314(6):570–81.PubMed Basaria S, et al. Effects of testosterone administration for 3 years on subclinical atherosclerosis progression in older men with low or low-normal testosterone levels: a randomized clinical trial. JAMA. 2015;314(6):570–81.PubMed
33.
Zurück zum Zitat Johnson JM, Nachtigall LB, Stern TA. The effect of testosterone levels on mood in men: a review. Psychosomatics. 2013;54(6):509–14.PubMed Johnson JM, Nachtigall LB, Stern TA. The effect of testosterone levels on mood in men: a review. Psychosomatics. 2013;54(6):509–14.PubMed
34.
Zurück zum Zitat Moffat SD, et al. Longitudinal assessment of serum free testosterone concentration predicts memory performance and cognitive status in elderly men. J Clin Endocrinol Metab. 2002;87(11):5001–7.PubMed Moffat SD, et al. Longitudinal assessment of serum free testosterone concentration predicts memory performance and cognitive status in elderly men. J Clin Endocrinol Metab. 2002;87(11):5001–7.PubMed
35.
Zurück zum Zitat Almeida OP, et al. One year follow-up study of the association between chemical castration, sex hormones, beta-amyloid, memory and depression in men. Psychoneuroendocrinology. 2004;29(8):1071–81.PubMed Almeida OP, et al. One year follow-up study of the association between chemical castration, sex hormones, beta-amyloid, memory and depression in men. Psychoneuroendocrinology. 2004;29(8):1071–81.PubMed
36.
Zurück zum Zitat Almeida OP, Flicker L. Testosterone and dementia: too much ado about too little data. J Br Menopause Soc. 2003;9(3):107–10.PubMed Almeida OP, Flicker L. Testosterone and dementia: too much ado about too little data. J Br Menopause Soc. 2003;9(3):107–10.PubMed
37.
Zurück zum Zitat Sih R, et al. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab. 1997;82(6):1661–7.PubMed Sih R, et al. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab. 1997;82(6):1661–7.PubMed
38.
Zurück zum Zitat Kenny AM, et al. Effects of transdermal testosterone on cognitive function and health perception in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci. 2002;57(5):M321–5.PubMed Kenny AM, et al. Effects of transdermal testosterone on cognitive function and health perception in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci. 2002;57(5):M321–5.PubMed
39.
Zurück zum Zitat Huang G, et al. Effects of long-term testosterone administration on cognition in older men with low or low-to-normal testosterone concentrations: a prespecified secondary analysis of data from the randomised, double-blind, placebo-controlled TEAAM trial. Lancet Diabetes Endocrinol. 2016;4(8):657–65.PubMed Huang G, et al. Effects of long-term testosterone administration on cognition in older men with low or low-to-normal testosterone concentrations: a prespecified secondary analysis of data from the randomised, double-blind, placebo-controlled TEAAM trial. Lancet Diabetes Endocrinol. 2016;4(8):657–65.PubMed
40.
Zurück zum Zitat Haddad RM, et al. Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc. 2007;82(1):29–39.PubMed Haddad RM, et al. Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc. 2007;82(1):29–39.PubMed
41.
Zurück zum Zitat Fernandez-Balsells MM, et al. Clinical review 1: Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2010;95(6):2560–75.PubMed Fernandez-Balsells MM, et al. Clinical review 1: Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2010;95(6):2560–75.PubMed
42.
Zurück zum Zitat Calof OM, et al. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci. 2005;60(11):1451–7.PubMed Calof OM, et al. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci. 2005;60(11):1451–7.PubMed
43.
Zurück zum Zitat Gagliano-Juca T, et al. Effects of testosterone replacement on electrocardiographic parameters in men: findings from two randomized trials. J Clin Endocrinol Metab. 2017;102(5):1478–85.PubMed Gagliano-Juca T, et al. Effects of testosterone replacement on electrocardiographic parameters in men: findings from two randomized trials. J Clin Endocrinol Metab. 2017;102(5):1478–85.PubMed
44.
Zurück zum Zitat Basaria S, et al. Adverse events associated with testosterone administration. N Engl J Med. 2010;363(2):109–22.PubMedPubMedCentral Basaria S, et al. Adverse events associated with testosterone administration. N Engl J Med. 2010;363(2):109–22.PubMedPubMedCentral
45.
Zurück zum Zitat Finkle WD, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One. 2014;9(1):e85805.PubMedPubMedCentral Finkle WD, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One. 2014;9(1):e85805.PubMedPubMedCentral
46.
Zurück zum Zitat Vigen R, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013;310(17):1829–36.PubMed Vigen R, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013;310(17):1829–36.PubMed
47.
Zurück zum Zitat Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin. 1972;22(4):232–40.PubMed Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin. 1972;22(4):232–40.PubMed
48.
Zurück zum Zitat Pechersky AV, et al. Androgen administration in middle-aged and ageing men: effects of oral testosterone undecanoate on dihydrotestosterone, oestradiol and prostate volume. Int J Androl. 2002;25(2):119–25.PubMed Pechersky AV, et al. Androgen administration in middle-aged and ageing men: effects of oral testosterone undecanoate on dihydrotestosterone, oestradiol and prostate volume. Int J Androl. 2002;25(2):119–25.PubMed
49.
Zurück zum Zitat Dobs AS, et al. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab. 1999;84(10):3469–78.PubMed Dobs AS, et al. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab. 1999;84(10):3469–78.PubMed
50.
Zurück zum Zitat Basaria S, Dobs AS. Risks versus benefits of testosterone therapy in elderly men. Drugs Aging. 1999;15(2):131–42.PubMed Basaria S, Dobs AS. Risks versus benefits of testosterone therapy in elderly men. Drugs Aging. 1999;15(2):131–42.PubMed
51.
Zurück zum Zitat Salam R, Kshetrimayum AS, Keisam R. Testosterone and metabolic syndrome: the link. Indian J Endocrinol Metab. 2012;16(Suppl 1):S12–9.PubMedPubMedCentral Salam R, Kshetrimayum AS, Keisam R. Testosterone and metabolic syndrome: the link. Indian J Endocrinol Metab. 2012;16(Suppl 1):S12–9.PubMedPubMedCentral
52.
Zurück zum Zitat Yao QM, et al. Testosterone level and risk of type 2 diabetes in men: a systematic review and meta-analysis. Endocr Connect. 2018;7(1):220–31.PubMed Yao QM, et al. Testosterone level and risk of type 2 diabetes in men: a systematic review and meta-analysis. Endocr Connect. 2018;7(1):220–31.PubMed
53.
Zurück zum Zitat Kelly DM, Jones TH. Testosterone and obesity. Obes Rev. 2015;16(7):581–606.PubMed Kelly DM, Jones TH. Testosterone and obesity. Obes Rev. 2015;16(7):581–606.PubMed
54.
Zurück zum Zitat Rossouw JE, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results. From the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–33.PubMed Rossouw JE, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results. From the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–33.PubMed
Metadaten
Titel
Is Testosterone Replacement Therapy in Older Men Effective and Safe?
verfasst von
Andriy Yabluchanskiy
Panayiotis D. Tsitouras
Publikationsdatum
08.10.2019
Verlag
Springer International Publishing
Erschienen in
Drugs & Aging / Ausgabe 11/2019
Print ISSN: 1170-229X
Elektronische ISSN: 1179-1969
DOI
https://doi.org/10.1007/s40266-019-00716-2

Weitere Artikel der Ausgabe 11/2019

Drugs & Aging 11/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.